Hopeful week for insiders who might be regretting buying US$1.9m of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) stock earlier this year

By
Simply Wall St
Published
May 09, 2022
NasdaqCM:NYMX
Source: Shutterstock

Insiders who bought US$1.9m worth of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) stock in the last year have seen some of their losses recouped as the stock gained 19% last week. However, the purchase is proving to be an expensive wager as insiders are yet to get ahead of their losses which currently stand at US$276k since the time of purchase.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for Nymox Pharmaceutical

The Last 12 Months Of Insider Transactions At Nymox Pharmaceutical

Notably, that recent purchase by James Robinson is the biggest insider purchase of Nymox Pharmaceutical shares that we've seen in the last year. That means that even when the share price was higher than US$1.41 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. James Robinson was the only individual insider to buy during the last year.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqCM:NYMX Insider Trading Volume May 9th 2022

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Nymox Pharmaceutical insiders own 45% of the company, currently worth about US$57m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Nymox Pharmaceutical Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Nymox Pharmaceutical. That's what I like to see! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Nymox Pharmaceutical. Every company has risks, and we've spotted 5 warning signs for Nymox Pharmaceutical (of which 3 don't sit too well with us!) you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.